TARGOVAX

Targovax AS develops active immunotherapy in the form of cancer vaccines. The lead candidate TG01 is currently in a phase I/II clinical trial in resectable pancreatic cancer. Patients are treated after operation, and the immune system is triggered to recognize cancer specific RAS mutations and kill the cancer cells. TG01 consists of peptides designed to trigger both a helper- and cytotoxic T-cell response in the patients, ensuring a broad and lasting immune response. The Targovax peptides are de... signed for induction of RAS mutation specific T-helper cells through presentation on HLA class II molecules on the surface of Antigen Presenting Cells (APCs), but also for natural processing to potential HLA class I epitopes and induction of RAS mutation specific cytotoxic T cells.The T helper (Th) cells have a central and critical role in coordination of immune reactions and are often referred to as the "generals" and "conductors" of the immune system. The drug candidate has a strong historical background including clinical data. The clinical data indicate both an increase of mean survival and long-term survivors. The drug is well tolerated with a low degree of side effects. Inventors of the technology and the Radium Hospital Research Foundation established Targovax in 2010.More